Cold' tumors are resistant to common immunotherapies. Researchers have uncovered a master regulator that can be manipulated to prevent tumor growth in mice.

The thymus is a crucial training ground for T-cells, the body's "white knights," where they learn to battle the various diseases they may encounter. Thymic function shrinks to nearly nothing as we age ...

Pancreatic cancer is a leading cause of cancer-related death, with a five-year survival rate of 13%. The high mortality is ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge.

FYARRO holds strong market potential, particularly in treating rare and aggressive cancers like PEComa, where treatment options are limited. As the first FDA-approved therapy for advanced PEComa ...

DelveInsight's "FYARRO Market Size, Forecast, and Market Insight Report" highlights the details around FYARRO, an mTOR ...

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the presentation of its investigational therapy QTORIN™ rapamycin 3.9% anhydrous gel for microcystic lymphatic malformations ...

In this work, the mechanism underlying the relationship between the mTOR signaling pathway and orthoflavivirus infection was reviewed from three perspectives: orthoflavivirus structure and life cycle, ...

CD47-amyloid-β-CD74 signaling is a key driver of adaptive immunosuppression in sepsis, suppressing B cells and impairing immunity. Blocking this pathway restores immune function and improves survival ...